OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

November 15th 2024

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

November 15th 2024

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

November 14th 2024

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

November 13th 2024

Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.

Dr Biachi on the Evolving Role for Surgery in CRC

November 12th 2024

Tiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.

Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC

November 12th 2024

Nicolas Girard, MD, discusses both de novo and acquired resistance alterations in HER2-altered non–small cell lung cancer.

Dr Jabbour on the FDA Approval of Obe-Cel for Adult Patients With Relapsed or Refractory B-cell Precursor ALL

November 11th 2024

Dr DeAngelo on the Integration of JAK Inhibitors in Myelofibrosis Management

November 11th 2024

Daniel DeAngelo, MD, discusses the integration of JAK inhibitors into clinical practice for patients with myelofibrosis.

Dr Sborov on CAR T-Cell Therapy–Specific Long-Term Treatment Effects in Myeloma

November 11th 2024

Douglas W. Sborov, MD, MS, discusses long-term treatment outcomes for patients with myeloma who received CAR T-cell therapy vs another treatment option.

Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma

November 9th 2024

Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

November 9th 2024

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.

Dr Badami on Factors Informing Treatment Selection in ccRCC and Non–ccRCC

November 8th 2024

Ami Umesh Badami, MD, discusses the factors that guide treatment decision-making for patients with clear cell or non–clear cell renal cell carcinoma.

Dr Thaker on the Role of the Glucocorticoid Pathway in Platinum-Resistant Ovarian Cancer

November 8th 2024

Premal Thaker, MD, MS, discusses the role of the glucocorticoid receptor pathway and the development of chemoresistance in ovarian cancer.

Dr Lee on the Surgical Implications of Molecular Testing in NSCLC

November 8th 2024

Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.

Dr Shore on the Rationale for the Duravelo-2 Trial in Metastatic Urothelial Cancer

November 8th 2024

Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Feldman on the Recognition of Racial Disparities in Breast Cancer

November 7th 2024

Sheldon M. Feldman, MD, discusses the recognition of racial disparities in breast cancer, as well as the mitigation of treatment-related toxicities.

Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC

November 7th 2024

Louis Crain Garrot, MD, discusses the role of lutetium Lu 177 in older patients with metastatic castration-resistant prostate cancer.

Dr Delforge on the Rationale for CARTITUDE-4 in Lenalidomide-Refractory Myeloma

November 7th 2024

Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.

Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma

November 7th 2024

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.